Skip to main content
. 2009 Jan 8;296(3):G572–G581. doi: 10.1152/ajpgi.90435.2008

Fig. 6.

Fig. 6.

A: plasma ALT activities were measured 6 h after intraperitoneal administration of 0.15 or 0.10 mmol/kg DQ and, in addition, 5% DMSO/PBS (vehicle) or 10 mg/kg of the JNK inhibitor SP-600125. Data represent means ± SE of n = 4–6 animals per group. B: Western blot analysis of c-Jun and p-c-Jun (indicator of JNK) before and 6 h after treatment with DQ and SP-600125.